Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database

Reference

• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• SenerSFFremgenAMenckHRWinchesterDPPancreatic cancer: A report of treatment and survival trends for 100313 patients diagnosed from 1985–1995 using the National Cancer DatabaseJ Am Coll Surg199918911710401733
   PubMed Web of Science ®Google Scholar
• MyrehaugSSahgalARussoSMStereotactic body radiotherapy for pancreatic cancer: Recent progress and future directionsExpert Rev Anticancer Ther201616552353026999329
   PubMed Web of Science ®Google Scholar
• RegineWFWinterKAAbramsRFluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trialAnn Surg Oncol20111851319132621499862
   PubMed Web of Science ®Google Scholar
• HermanJMSwartzMJHsuCCAnalysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins HospitalJ Clin Oncol200826213503351018640931
   PubMed Web of Science ®Google Scholar
• OettleHNeuhausPHochhausAAdjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trialJAMA2013310141473148124104372
   PubMed Web of Science ®Google Scholar
• TsengJFRautCPLeeJEPancreaticoduodenectomy with vascular resection: margin status and survival durationJ Gastrointest Surg20048893594915585381
   PubMed Web of Science ®Google Scholar
• HoyerMRoedHSengelovLPhase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinomaRadiother Oncol2005761485315990186
   PubMed Web of Science ®Google Scholar
• TemperoMAMalafaMPAl-HawaryMPancreatic adenocarcinoma. Version 2. 2017, NCCN Clinical Practice Guidelines in OncologyJ Natl Compr Canc Netw20171581028106128784865
   PubMed Web of Science ®Google Scholar
• UenoHOkusakaTIkedaMTakezakoYMorizaneCAn early phase II study of S-1 in patients with metastatic pancreatic cancerOncology2005682–317117816006754
   PubMed Web of Science ®Google Scholar
• UenoHIokaTIkedaMRandomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST studyJ Clin Oncol201331131640164823547081
   PubMed Web of Science ®Google Scholar
• MorizaneCOkusakaTFuruseJA phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancerCancer Chemother Pharmacol200963231331918398614
   PubMed Web of Science ®Google Scholar
• SudoKYamaguchiTNakamuraKDendaTHaraTIshiharaTYokosukaOPhase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancerCancer Chemother Pharmacol201167224925420352216
   PubMed Web of Science ®Google Scholar
• KharofaJTsaiSKellyTNeoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancerRadiother Oncol20141131414625443499
   PubMed Web of Science ®Google Scholar
• CoxJDStetzJPajakTFToxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)Int J Radiat Oncol Biol Phys1995315134113467713792
   PubMed Web of Science ®Google Scholar
• QiQZhuangLShenYA novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapyCancer2016122142158216727152949
   PubMed Web of Science ®Google Scholar
• LeeSHChungMJKimBThe significance of the prognostic nutritional index for all stages of pancreatic cancerNutr Cancer201769351251927967240
   PubMed Web of Science ®Google Scholar
• GengYQiQSunMChenHWangPChenZPrognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancerEur J Surg Oncol201541111508151426343824
   PubMed Web of Science ®Google Scholar
• CharlsonMSzatrowskiTPPetersonJGoldJValidation of a combined comorbidity indexJ Clin Epidemiol19944711124512517722560
   PubMed Web of Science ®Google Scholar
• Dias-SantosDFerroneCRZhengHLillemoeKDFernández-Del CastilloCThe Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancerSurgery2015157588188725704415
   PubMed Web of Science ®Google Scholar
• FerroneCRFinkelsteinDMThayerSPMuzikanskyAFernandezdelCastilloCWarshawALPerioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinomaJ Clin Oncol200624182897290216782929
   PubMed Web of Science ®Google Scholar
• Von HoffDDRamanathanRKBoradMJGemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trialJ Clin Oncol201129344548455421969517
   PubMed Web of Science ®Google Scholar
• CloydJMWangHEggerMEAssociation of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinomaJAMA Surg2017152111048105628700784
   PubMed Web of Science ®Google Scholar
• ZhuXJuXCaoFSafety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trialBMJ Open2016612e013220
   PubMed Web of Science ®Google Scholar
• ZhuXLiFJuXPrognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancerCancer Med20176102263227028834410
   PubMed Web of Science ®Google Scholar
• BenedictSHYeniceKMFollowillDStereotactic body radiation therapy: the report of AAPM Task Group 101Med Phys20103784078410120879569
   PubMed Web of Science ®Google Scholar
• LeksellLThe stereotaxic method and radiosurgery of the brainActa Chir Scand1951102431631914914373
   PubMedGoogle Scholar
• HartmannGHSchlegelWSturmVKoberBPastyrOLorenzWJCerebral radiation surgery using moving field irradiation at a linear accelerator facilityInt J Radiat Oncol Biol Phys1985116118511923997600
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPStockenDDFriessHEuropean Study Group for Pancreatic CancerA randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancerN Engl J Med2004350121200121015028824
   PubMed Web of Science ®Google Scholar
• Van LaethemJLHammelPMornexFAdjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II studyJ Clin Oncol201028294450445620837948
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPStockenDDBassiCEuropean Study Group for Pancreatic CancerAdjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJAMA2010304101073108120823433
   PubMed Web of Science ®Google Scholar
• UenoHKosugeTMatsuyamaYA randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBr J Cancer2009101690891519690548
   PubMed Web of Science ®Google Scholar
• YoshitomiHTogawaAKimuraFPancreatic Cancer Chemotherapy Program of the Chiba University Department of General Surgery Affiliated Hospital GroupA randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancerCancer200811392448245618823024
   PubMed Web of Science ®Google Scholar
• PalmerDHStockenDDHewittHA randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatinAnn Surg Oncol20071472088209617453298
   PubMed Web of Science ®Google Scholar
• SchmidtJAbelUDebusJOpen-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinomaJ Clin Oncol201230334077408323008325
   PubMed Web of Science ®Google Scholar
• GolcherHBrunnerTBWitzigmannHNeoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer. Results of the first prospective randomized phase II trialStrahlenther Onkol2015191171625252602
   PubMed Web of Science ®Google Scholar
• ReniMBalzanoGAprileGAdjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: A randomized phase II trialAnn Surg Oncol20121972256226322237835
   PubMed Web of Science ®Google Scholar
• HongTSRyanDPBorgerDRA phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinomaInt J Radiat Oncol Biol Phys201489483083824867540
   PubMed Web of Science ®Google Scholar
• DemariaSFormentiSCRadiation as an immunological adjuvant: Current evidence on dose and fractionationFront Oncol2012215323112958
   PubMedGoogle Scholar
• PoppIGrosuALNiedermannGDudaDGImmune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implicationsRadiother Oncol2016120218519427495145
   PubMed Web of Science ®Google Scholar
• KrishnanSChadhaASSuhYFocal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiationInt J Radiat Oncol Biol Phys201694475576526972648
   PubMed Web of Science ®Google Scholar